Nephrotoxicity Clinical Trial
Official title:
Effect of Huaier Granule on Nephrotoxicity Associated With Anti-angiogenesis Targeted Therapy for Advanced Hepatobiliary Malignancies: a Single-arm, Single-center, Exploratory Study.
This is a prospective, single-arm, single-center, exploratory study. The purpose of this study is to explore the effect of Huaier Granule on nephrotoxicity associated with anti-angiogenesis targeted therapy for advanced hepatobiliary malignancies.
China is a country with a high incidence of liver cancer, and the incidence of primary liver cancer ranks the fourth among malignant tumors in China. Hepatocellular carcinoma (HCC) is the main type of liver cancer, accounting for 75% to 85%. About 39.0%-53.6% of HCC patients were already advanced when first visit and had lost the opportunity to receive radical treatment. Currently, anti-angiogenesis targeted drugs are recommended for the first- or second-line treatment of advanced hepatocellular carcinoma. Biliary tract carcinoma are rare, accounting for about 3% of all digestive system malignancies. BTC are aggressive and were usually found in advanced stage, with a 5-year survival rate less than 5%. For advanced BTC, chemotherapy is the mainly systematic therapy recommended by current guidelines, targeted therapy and immunotherapy have shown efficacy in the exploration of the first-line and post-line of BTC. Anti-angiogenesis targeted drugs including lenvatinib are recommended for the first- or second-line treatment of advanced BTC. Kidney injury is one of the common adverse reactions of anti-angiogenesis targeted drugs, among which proteinuria is one of the most common adverse reactions. Multiple key clinical studies have shown that the incidence of proteinuria associated with targeted therapy ranges from 10% to 51%, and the incidence of drug reduction or interruption due to proteinuria ranges from 0.9% to 17%. Huaier is an extract from a medicinal fungus. The main effective component of Huai Qi Huang granule is Trametes Robiniophila Murr, which has been used in the treatment of chronic kidney disease for more than ten years. It was found that the effect of Huai Qi Huang granule alone or combined with RASI in the treatment of proteinuria was better than conventional treatment. The effective component of Huaier granule is also Trametes Robiniophila Murr, and its content is higher than that of Huai Qi Huang granule. Therefore, it is speculated that Huaier granule have a certain effect on anti-angiogenesis targeted therapy associated proteinuria in advanced hepatobiliary malignancies. In this study, 1 research centers will participate. This study planned to enroll 53 participants. All the participants will be treated with Huaier granule. In this study, participants will be followed up for 24 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT06360666 -
Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia
|
||
| Recruiting |
NCT01624324 -
Aminoglycoside Plasma Level Measurement in Neonates With Infection
|
N/A | |
| Completed |
NCT01216540 -
Vancomycin-Associated Nephrotoxicity
|
||
| Recruiting |
NCT03817970 -
Cisplatin Disposition and Kidney Injury
|
Phase 3 | |
| Completed |
NCT01467154 -
Evaluation of Intravenous N-acetylcysteine to Prevent Contrast Media Induced Nephrotoxicity in an Emergency Center
|
N/A | |
| Recruiting |
NCT03480971 -
Treatment of Radiation and Cisplatin Induced Toxicities With Tempol
|
Phase 2 | |
| Recruiting |
NCT02528448 -
0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis
|
Phase 4 | |
| Completed |
NCT02103855 -
Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
|
Phase 4 | |
| Recruiting |
NCT06153147 -
KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors (CCS)
|
||
| Completed |
NCT04354467 -
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU
|
||
| Not yet recruiting |
NCT03438214 -
Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients
|
Phase 4 | |
| Completed |
NCT03527160 -
Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications
|
||
| Completed |
NCT01848457 -
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
|
Phase 2 |